Investigational Drug Information for Danicopan
✉ Email this page to a colleague
What is the development status for investigational drug Danicopan?
Danicopan is an investigational drug.
There have been 24 clinical trials for Danicopan.
The most recent clinical trial was a Phase 2 trial, which was initiated on December 16th 2020.
The most common disease conditions in clinical trials are Hemoglobinuria, Paroxysmal, Hemoglobinuria, and Glomerulonephritis. The leading clinical trial sponsors are Alexion Pharmaceuticals, Achillion, a wholly owned subsidiary of Alexion, and Achillion Pharmaceuticals.
There are eight US patents protecting this investigational drug and one hundred and thirty-nine international patents.
Summary for Danicopan
US Patents | 8 |
International Patents | 139 |
US Patent Applications | 31 |
WIPO Patent Applications | 8 |
Japanese Patent Applications | 1 |
Clinical Trial Progress | Phase 2 (2020-12-16) |
Vendors | 24 |
Recent Clinical Trials for Danicopan
Title | Sponsor | Phase |
---|---|---|
A Long-term Safety and Efficacy Study of Danicopan as an Add-on Therapy to Complement Component 5 Inhibitor (C5i) in Participants With PNH | Alexion Pharmaceuticals | Phase 3 |
A Study of Danicopan in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration | Alexion Pharmaceuticals | Phase 2 |
ACTIV-5 / Big Effect Trial (BET-C) for the Treatment of COVID-19 | National Institute of Allergy and Infectious Diseases (NIAID) | Phase 2 |
Clinical Trial Summary for Danicopan
Top disease conditions for Danicopan
Top clinical trial sponsors for Danicopan
US Patents for Danicopan
Drugname | Patent Number | Patent Title | Patent Assignee | Estimated Expiration |
---|---|---|---|---|
Danicopan | ⤷ Try a Trial | Aryl, heteroaryl, and heterocyclic compounds for treatment of medical disorders | Achillion Pharmaceuticals, Inc. (New Haven, CT) | ⤷ Try a Trial |
Danicopan | ⤷ Try a Trial | Aryl, heteroaryl, and heterocyclic compounds for treatment of complement mediated disorders | Achillion Pharmaceuticals, Inc. (New Haven, CT) | ⤷ Try a Trial |
Danicopan | ⤷ Try a Trial | Aryl, heteroaryl, and heterocyclic compounds for treatment of complement mediated disorders | Achillion Pharmaceuticals, Inc. (New Haven, CT) | ⤷ Try a Trial |
Danicopan | ⤷ Try a Trial | Aryl, heteroaryl, and heterocyclic compounds for treatment of medical disorders | Achillion Pharmaceuticals, Inc. (New Haven, CT) | ⤷ Try a Trial |
Danicopan | ⤷ Try a Trial | Aryl, heteroaryl, and heterocyclic compounds for treatment of complement mediated disorders | Achillion Pharmaceuticals, Inc. (New Haven, CT) | ⤷ Try a Trial |
Danicopan | ⤷ Try a Trial | Aryl, heteroaryl, and heterocyclic compounds for treatment of immune and inflammatory disorders | Achillion Pharmaceuticals, Inc. (New Haven, CT) | ⤷ Try a Trial |
>Drugname | >Patent Number | >Patent Title | >Patent Assignee | >Estimated Expiration |
International Patents for Danicopan
Drugname | Country | Document Number | Estimated Expiration | Related US Patent |
---|---|---|---|---|
Danicopan | Argentina | AR106018 | 2035-08-26 | ⤷ Try a Trial |
Danicopan | Australia | AU2016311425 | 2035-08-26 | ⤷ Try a Trial |
Danicopan | Australia | AU2021202728 | 2035-08-26 | ⤷ Try a Trial |
Danicopan | Canada | CA2996415 | 2035-08-26 | ⤷ Try a Trial |
Danicopan | China | CN108024992 | 2035-08-26 | ⤷ Try a Trial |
Danicopan | China | CN114044800 | 2035-08-26 | ⤷ Try a Trial |
>Drugname | >Country | >Document Number | >Estimated Expiration | >Related US Patent |